The TCF1high T cells can be efficiently rescued and acquire a stronger effector profile and anti-tumor activity by the treatment with IC inhibitors (e.g., anti-PD-1, anti-PDL-1, anti-CTLA-4 mAbs), or the combination of the latter with vaccine therapy containing mutated tumor neo-antigens (58). Here, CTLA4 is linked to neoplasm.